Search PubMed⌕ Search

Biomedical subjects

S Ferrone

Publications and source records attributed to S Ferrone.

At least 307 records · Page 17Linked to original sources
PubMed1983

Selective in vitro toxicity of purothionin conjugated to the monoclonal antibody 225.28S to a human high-molecular-weight melanoma-associated antigen.

The toxic agent purothionin was conjugated to the monoclonal antibody 225.28S to a human high-molecular-weight melanoma-accociated antigen. The toxic conjugate displayed in vitro toxicity to cultured human Colo 38 melanoma cells as indicated by reduced uptake of 3H-thymidine following a 24-h incubation and loss of cell viability following a 7-day incubation. The effect is dose-dependent and is specific since addition of the toxic conjugate to a cultured Raji B lymphoid cells did not affect their 3H-thymidine uptake or their viability.

Antibodies, Monoclonal↗
PubMed1983

Immunochemical characterization of a human high molecular weight--melanoma associated antigen identified with monoclonal antibodies.

Sodium dodecyl sulfate polyacrylamide gel analysis of a high molecular weight (HMW) human melanoma associated antigen (MAA) defined by murine monoclonal antibodies revealed a number of distinct polypeptides ranging from 80,000 up to 280,000 daltons, in addition to an extremely heterogeneous group of components distributed over a wide range in apparent molecular weight (300,000-700,000 daltons). The 280,000 dalton and the larger heterogeneous molecular weight material are glycosylated since they are labeled with 3H-sugars. The HMW-MAA is readily solubilized in the absence of detergents and the entire series of polypeptides fractionates together in the void volume of a Sephadex G200 column. Peptide maps of the various polypeptides of the HMW-MAA, generated by Staphylococcus aureus V-8 protease, are essentially the same except that some of the proteolytic fragments derived from the lower molecular weight polypeptides (80,000 daltons) are present in greater amounts than are similar fragments derived from the larger molecular weight polypeptides; the latter finding suggests that the complexity in molecular weight of the MAA may reflect combinations of several base subunits. Proteolytic cleavage of the HMW-MAA generates a number of peptides ranging in molecular weight from 77,000 daltons to less than 12,000 daltons, which still react with monoclonal antibodies and can distinguish monoclonal antibodies specific for different antigenic determinants of this MAA.

Antibodies, Monoclonal↗
PubMed1983

The monoclonal antibody CR11-351 discriminates HLA-A2 variants identified by T cells.

Serologic and immunochemical assays have shown that the monoclonal antibody (MoAb) CR11-351 recognizes a determinant expressed by HLA-A2 and A28 alloantigens. The MoAb CR11-351 blocks the cytotoxicity of some, but not all, anti-HLA-A2 and anti-HLA-A28 alloantisera tested. These findings suggest that each allospecificity consists of several determinants, only some of which are spatially close to the determinant defined by the MoAb CR11-351. The binding of the MoAb CR11-351 to HLA-A2 lymphoid cells is not effected by their precoating with the HLA-A, B-specific MoAb CR10-214, Q6/64, and 6/31 but is enhanced by at least 20% by the MoAb CR10-131, CR10-402 and by the beta 2-m-specific MoAb NAMB-1. The MoAb CR11-351 did not react with one of four HLA-A2 variants which are indistinguishable with conventional anti-HLA-A2 sera, but are not recognized by "normal" HLA-A2-restricted cytotoxic T cells and possess structurally distinct HLA-A2 heavy chains. Therefore the MoAb CR11-351 provides the first evidence of a serologically detectable difference between the four HLA-A2 variants and "normal" HLA-A2 antigens.

Antibodies, Monoclonal↗
PubMed1983

Inhibitory effect of a low dose of prednisone on PHA-induced Ia antigen expression by human T cells and on proliferation of T cells stimulated with autologous PHA-T cells.

Administration of a small dose of prednisone markedly reduced (1) the PHA-induced expression of Ia antigens by T cells, (2) the stimulatory activity of Ia antigen-bearing T cells in autologous and allogeneic mixed lymphocyte reactions (MLRs), and (3) the proliferative response of T cells stimulated with autologous PHA-activated T cells or autologous or allogeneic non-T cells. The inhibitory effects of prednisone are reversible and are not detectable on T cells isolated from blood drawn 24 hr following prednisone administration. The kinetics of the prednisone-mediated inhibition of MLRs with autologous PHA-T cells is different from that of MLRs with autologous non-T cells. These data in conjunction with the information available in the literature suggest that the mechanisms underlying these two types of autologous MLRs are different.

Adult↗
PubMed1983

Human T lymphocytes in aging and malignancy: abnormalities in PHA-induced Ia antigen expression and in functional activity in autologous and allogeneic MLR.

T lymphocytes from patients with solid tumors and from aged donors are abnormal in their expression of Ia antigens following in vitro stimulation with phytohemagglutinin (PHA). Ia antigens were not detected on PHA-activated T lymphocytes from 15 of 27 patients with solid tumors. The abnormality in T lymphocytes from 25 donors older than 60 years was evidenced by a reduction in the percentage of T cells acquiring Ia antigens following stimulation with suboptimal amounts of PHA and by a delayed appearance of those antigens. In both groups of donors the defect in Ia antigen expression by PHA-activated T cells did not correlate with the reduced [3H]thymidine uptake. PHA-activated T cells from aged donors and from patients with solid tumors were poorly stimulatory in autologous and allogenic mixed lymphocyte reactions. Furthermore, T lymphocytes from these two groups of donors displayed a reduced proliferative response to autologous non-T cells, but a normal proliferative response to allogeneic PHA-activated T cells and to non-T cells from control subjects.

Adult↗
PubMed1983

HLA-D restriction of antigen-specific proliferative T cell responses. Inhibitory activity of antisera against HLA determinants or stimulatory antigen.

The specificity of the inhibitory activity of anti HLA-DR antisera on the proliferative response of human T cells to soluble antigens has been recently challenged. Furthermore, there are conflicting reports about the effect of antisera to the stimulatory antigen. Therefore, we investigated the inhibitory activity of different antisera on the proliferative response of T lymphocytes from sensitized donors to the antigens HSV and PPD. Alloantisera to DR specificities shared between antigen presenting cells (APC) and T cells displayed a strong inhibitory activity: alloantisera to HLA-DR specificities expressed only by APC or the T cell donor displayed lower or no inhibitory activity. Monoclonal antibodies to monomorphic determinants of HLA-DR molecules were inhibitory, but only when used at a high concentration. Antisera to HLA-ABC molecules and to HSV displayed little if any inhibition. These findings provide further evidence that the HLA-DR molecules as such in the APC membrane, which were also present during initial sensitization, are restriction elements for T cells.

Animals↗
PubMed1983

Role of distinct domains of Ia antigens in autologous and allogeneic mixed lymphocyte reactions.

Murine monoclonal antibodies (MoAb) to distinct determinants of human Ia antigens and low doses of prednisone induce different effects on the autologous mixed lymphocyte reaction (MLR), stimulated by PHA-T cells or by non-T cells, and on allogeneic MLRs. These results suggest that distinct domains of Ia antigens and/or mechanisms are involved in these types of MLRs.

Antibodies, Monoclonal↗
PubMed1983

Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells.

Surgically removed normal and malignant mammary tissues and human breast carcinoma cell lines were tested in binding assays with monoclonal antibodies to HLA-A,B,C antigens, beta 2-microglobulin, HLA-DR antigens, and tumor-associated antigens; the latter included a Mr 280,000, a Mr 94,000, and a Mr 85,000 membrane-bound glycoprotein and a cytoplasmic antigen. HLA-A,B antigens, beta 2-microglobulin, HLA-DR antigens, and the cytoplasmic antigen are expressed by normal mammary cells. Their malignant transformation may be associated with quantitative changes in the expression of these antigens and with the appearance of Mr 94,000 and Mr 85,000 glycoproteins. The Mr 280,000 glycoprotein was detected on only one of the breast carcinoma cell lines tested. Analysis of primary tumors and autologous axillary lymph node metastasis from 13 patients has shown differences in the expression of all the antigens tested between primary and metastatic lesions.

Adult↗
PubMed1983

Double determinant immunoassay to measure a human high-molecular-weight melanoma-associated antigen.

Using monoclonal antibodies to distinct determinants of a human high-molecular weight melanoma-associated antigen (HMW-MAA), a double determinant immunoassay has been developed. The assay is specific and reproducible. Its sensitivity is influenced by the incubation time of antibodies with antigen sources and the combination of antibodies, as well as by the pH of the buffer and the incubation time used to coat plates with antibodies. Testing with the double determinant immunoassay of Nonidet P-40 extracts of human cell lines and of surgically removed normal and malignant tissues has confirmed the restricted tissue distribution of the HMW-MAA. In addition, significant differences have been found in the level of HMW-MAA in melanoma cell lines, as well as in melanoma lesions removed from different patients and from different sites of a given patient. The amount of HMW-MAA shed by various melanoma cell lines does not correlate with their cell surface expression and with their level in Nonidet P-40 extracts. Interferon and hyperthermia increase the shedding of the HMW-MAA by melanoma cells.

Antibodies, Monoclonal↗
PubMed1983

Antigenic heterogeneity of skin tumors of nonmelanocyte origin: analysis with monoclonal antibodies to tumor-associated antigens and to histocompatibility antigens.

Surgically removed benign and malignant human skin lesions of nonmelanocyte origin have been tested with monoclonal antibodies to la antigens, to the HLA-A,B antigenic molecular complex, and to melanoma-associated antigen(s) (MAA). MAA include a high-molecular-weight (HMW) MAA, a 115,000-molecular-weight MAA, a 94,000-molecular-weight MAA, and a cytoplasmic MAA. Indirect immunofluorescence was used as the assay system because of the limited amount of tissue available. When the amount of tissue available was sufficient, double determinant immunoassays (DDIA) were used to quantitate the level of the HMW MAA and of the cytoplasmic MAA. The results of the DDIA were in agreement with those of indirect immunofluorescence in more than 75% of the cases. Malignant skin tumors of various histiotypes displayed three types of changes: 1) appearance of la antigens and cytoplasmic MAA, 2) increase in the level of the HMW MAA, of a 115,000- and a 100,000-molecular-weight MAA, and 3) reduction in the level of HLA-A,B antigens and beta 2-microglobulin. A significant heterogeneity was found in the antigenic profile among various lesions of a given histiotype as well as among tumor cells within a given lesion.

Aged↗
PubMed1983

Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions.

The antigenic heterogeneity of primary and metastatic lesions surgically removed from nine patients with nodular melanoma was investigated by using monoclonal antibodies to HLA-A, B antigens, to beta 2-microglobulin, to Ia antigens, and to melanoma-associated antigens (MAA). The latter include three types of membrane-bound MAA and a cytoplasmic MAA. In spite of an homogeneous morphologic appearance, multiple lesions removed from the same patient differed significantly in their reactivity with the panel of monoclonal antibodies in indirect immunofluorescence test. The extent of antigenic heterogeneity did not correlate with melanin synthesis, site of origin of the primary tumor, site of metastatic foci, or treatment, but was less marked in patients carrying the primary tumor. The antigenic heterogeneity of multiple lesions removed from one patient and the independent expression of the various types of MAA investigated suggest that combinations of monoclonal antibodies to MAA may be more effective than single antibodies for radioimaging and immunotherapy.

Antibodies, Monoclonal↗